[8-K/A] Harvard Bioscience Inc Amends Material Event Report
Harvard Bioscience (HBIO) filed an amended Form 8-K to restate Item 3.01 and confirm that Nasdaq has formally determined the company is out of compliance with Listing Rule 5605(c)(2)(A), which requires at least three independent directors on the audit committee. The shortfall was triggered by director Alan Edrick’s resignation on 10 Jun 2025, leaving only two audit-committee members. Nasdaq’s notice was received on 26 Jun 2025.
HBIO states it will appoint a new, fully independent director “as expeditiously as practicable” and will rely on the cure period in Rule 5605(c)(4), giving the company until the earlier of its next annual shareholders’ meeting or 10 Jun 2026 to regain compliance. Until then, the company remains subject to potential delisting if it fails to add a qualified director within the allowed timeframe. No financial statements, earnings metrics or transactional details were included in this filing.
Harvard Bioscience (HBIO) ha presentato un modulo 8-K modificato per rettificare l'Elemento 3.01 e confermare che Nasdaq ha formalmente determinato che la società è non conforme alla Regola di Quotazione 5605(c)(2)(A), che richiede almeno tre amministratori indipendenti nel comitato di revisione. La carenza è stata causata dalle dimissioni del direttore Alan Edrick il 10 giugno 2025, lasciando solo due membri nel comitato di revisione. La notifica di Nasdaq è stata ricevuta il 26 giugno 2025.
HBIO dichiara che nominerà un nuovo direttore completamente indipendente "nel più breve tempo possibile" e si avvarrà del periodo di rimedio previsto dalla Regola 5605(c)(4), che concede alla società tempo fino al prossimo assemblea annuale degli azionisti o al 10 giugno 2026, qualunque sia la data precedente, per tornare in conformità. Fino ad allora, la società rimane soggetta a un possibile delisting se non aggiunge un direttore qualificato entro il termine previsto. In questo deposito non sono stati inclusi rendiconti finanziari, dati sugli utili o dettagli transazionali.
Harvard Bioscience (HBIO) presentó un Formulario 8-K enmendado para rectificar el Punto 3.01 y confirmar que Nasdaq ha determinado formalmente que la empresa está en incumplimiento de la Regla de Listado 5605(c)(2)(A), la cual exige al menos tres directores independientes en el comité de auditoría. La falta se originó por la renuncia del director Alan Edrick el 10 de junio de 2025, quedando solo dos miembros en el comité de auditoría. La notificación de Nasdaq se recibió el 26 de junio de 2025.
HBIO indica que nombrará un nuevo director completamente independiente "tan pronto como sea posible" y se acogerá al período de corrección establecido en la Regla 5605(c)(4), otorgando a la empresa hasta la fecha de su próxima junta anual de accionistas o el 10 de junio de 2026, lo que ocurra primero, para volver a cumplir. Hasta entonces, la empresa está sujeta a posible exclusión si no incorpora un director calificado dentro del plazo permitido. Este informe no incluye estados financieros, métricas de ganancias ni detalles de transacciones.
하버드 바이오사이언스(HBIO)는 수정된 Form 8-K를 제출하여 항목 3.01을 정정하고 나스닥이 회사가 상장 규칙 5605(c)(2)(A)을 준수하지 못했다는 공식 결정을 내렸음을 확인했습니다. 이 규칙은 감사위원회에 최소 세 명의 독립 이사가 있어야 한다고 규정합니다. 이 부족 사유는 2025년 6월 10일 이사 Alan Edrick의 사임으로 인해 발생했으며, 감사위원회 구성원이 두 명만 남게 되었습니다. 나스닥의 통지는 2025년 6월 26일에 접수되었습니다.
HBIO는 "가능한 한 신속하게" 완전한 독립 이사를 임명할 계획이며, 규칙 5605(c)(4)의 구제 기간을 활용하여 다음 연례 주주총회 또는 2026년 6월 10일 중 빠른 시점까지 준수를 회복할 예정입니다. 그때까지 회사는 허용된 기간 내에 적격 이사를 추가하지 못할 경우 상장 폐지 가능성에 노출됩니다. 이 제출서류에는 재무제표, 수익 지표 또는 거래 내역이 포함되지 않았습니다.
Harvard Bioscience (HBIO) a déposé un formulaire 8-K modifié pour rectifier l’élément 3.01 et confirmer que le Nasdaq a officiellement déterminé que la société est en non-conformité avec la règle de cotation 5605(c)(2)(A), qui exige au moins trois administrateurs indépendants au sein du comité d’audit. Ce manquement a été provoqué par la démission du directeur Alan Edrick le 10 juin 2025, laissant seulement deux membres au comité d’audit. L’avis du Nasdaq a été reçu le 26 juin 2025.
HBIO indique qu’elle nommera un nouveau directeur entièrement indépendant « aussi rapidement que possible » et s’appuiera sur la période de correction prévue par la règle 5605(c)(4), accordant à la société jusqu’à la prochaine assemblée annuelle des actionnaires ou au 10 juin 2026, selon la première échéance, pour retrouver la conformité. Jusqu’à cette date, la société reste exposée à un éventuel retrait de cotation si elle ne nomme pas un directeur qualifié dans le délai imparti. Aucun état financier, indicateur de résultat ou détail transactionnel n’a été inclus dans ce dépôt.
Harvard Bioscience (HBIO) hat ein geändertes Formular 8-K eingereicht, um Punkt 3.01 zu berichtigen und zu bestätigen, dass die Nasdaq formell festgestellt hat, dass das Unternehmen gegen die Listing-Regel 5605(c)(2)(A) verstößt, die mindestens drei unabhängige Direktoren im Prüfungsausschuss vorschreibt. Der Mangel entstand durch den Rücktritt des Direktors Alan Edrick am 10. Juni 2025, wodurch nur noch zwei Mitglieder im Prüfungsausschuss verbleiben. Die Benachrichtigung von Nasdaq wurde am 26. Juni 2025 erhalten.
HBIO erklärt, dass es "so schnell wie möglich" einen neuen, vollständig unabhängigen Direktor ernennen wird und sich auf die Heilungsfrist in Regel 5605(c)(4) beruft, die dem Unternehmen bis zur nächsten jährlichen Hauptversammlung oder zum 10. Juni 2026, je nachdem, welches Datum früher eintritt, Zeit gibt, die Compliance wiederherzustellen. Bis dahin bleibt das Unternehmen potenziell von einem Delisting bedroht, falls kein qualifizierter Direktor innerhalb des erlaubten Zeitrahmens hinzugefügt wird. In dieser Einreichung sind keine Finanzberichte, Gewinnkennzahlen oder Transaktionsdetails enthalten.
- Cure period until 10 Jun 2026 gives the company sufficient time to recruit an independent director and avoid immediate delisting risk.
- Nasdaq non-compliance notice increases the risk of eventual delisting if an independent director is not appointed in time.
- Audit-committee vacancy signals a governance weakness that could affect investor confidence and institutional ownership thresholds.
Insights
TL;DR: Nasdaq audit-committee shortfall elevates governance risk; curable within a year but negative for investor sentiment.
This amended 8-K confirms that HBIO now has an official Nasdaq deficiency notice under Rule 5605(c)(2)(A). Losing a qualified audit-committee member is immediately material because audit oversight is central to investor confidence. While the rule grants up to one year—or the next AGM—to remedy the gap, the company has not yet named a replacement. Historically, most issuers resolve such issues well before the deadline, but failure would result in a hearing process and potential delisting. Until a new independent director is appointed, rating agencies and some institutional investors may impose governance penalties, potentially widening the firm’s cost of capital. The risk is concentrated in reputational impact rather than liquidity, yet any hint of delisting can depress share liquidity and valuation multiples in the near term.
Harvard Bioscience (HBIO) ha presentato un modulo 8-K modificato per rettificare l'Elemento 3.01 e confermare che Nasdaq ha formalmente determinato che la società è non conforme alla Regola di Quotazione 5605(c)(2)(A), che richiede almeno tre amministratori indipendenti nel comitato di revisione. La carenza è stata causata dalle dimissioni del direttore Alan Edrick il 10 giugno 2025, lasciando solo due membri nel comitato di revisione. La notifica di Nasdaq è stata ricevuta il 26 giugno 2025.
HBIO dichiara che nominerà un nuovo direttore completamente indipendente "nel più breve tempo possibile" e si avvarrà del periodo di rimedio previsto dalla Regola 5605(c)(4), che concede alla società tempo fino al prossimo assemblea annuale degli azionisti o al 10 giugno 2026, qualunque sia la data precedente, per tornare in conformità. Fino ad allora, la società rimane soggetta a un possibile delisting se non aggiunge un direttore qualificato entro il termine previsto. In questo deposito non sono stati inclusi rendiconti finanziari, dati sugli utili o dettagli transazionali.
Harvard Bioscience (HBIO) presentó un Formulario 8-K enmendado para rectificar el Punto 3.01 y confirmar que Nasdaq ha determinado formalmente que la empresa está en incumplimiento de la Regla de Listado 5605(c)(2)(A), la cual exige al menos tres directores independientes en el comité de auditoría. La falta se originó por la renuncia del director Alan Edrick el 10 de junio de 2025, quedando solo dos miembros en el comité de auditoría. La notificación de Nasdaq se recibió el 26 de junio de 2025.
HBIO indica que nombrará un nuevo director completamente independiente "tan pronto como sea posible" y se acogerá al período de corrección establecido en la Regla 5605(c)(4), otorgando a la empresa hasta la fecha de su próxima junta anual de accionistas o el 10 de junio de 2026, lo que ocurra primero, para volver a cumplir. Hasta entonces, la empresa está sujeta a posible exclusión si no incorpora un director calificado dentro del plazo permitido. Este informe no incluye estados financieros, métricas de ganancias ni detalles de transacciones.
하버드 바이오사이언스(HBIO)는 수정된 Form 8-K를 제출하여 항목 3.01을 정정하고 나스닥이 회사가 상장 규칙 5605(c)(2)(A)을 준수하지 못했다는 공식 결정을 내렸음을 확인했습니다. 이 규칙은 감사위원회에 최소 세 명의 독립 이사가 있어야 한다고 규정합니다. 이 부족 사유는 2025년 6월 10일 이사 Alan Edrick의 사임으로 인해 발생했으며, 감사위원회 구성원이 두 명만 남게 되었습니다. 나스닥의 통지는 2025년 6월 26일에 접수되었습니다.
HBIO는 "가능한 한 신속하게" 완전한 독립 이사를 임명할 계획이며, 규칙 5605(c)(4)의 구제 기간을 활용하여 다음 연례 주주총회 또는 2026년 6월 10일 중 빠른 시점까지 준수를 회복할 예정입니다. 그때까지 회사는 허용된 기간 내에 적격 이사를 추가하지 못할 경우 상장 폐지 가능성에 노출됩니다. 이 제출서류에는 재무제표, 수익 지표 또는 거래 내역이 포함되지 않았습니다.
Harvard Bioscience (HBIO) a déposé un formulaire 8-K modifié pour rectifier l’élément 3.01 et confirmer que le Nasdaq a officiellement déterminé que la société est en non-conformité avec la règle de cotation 5605(c)(2)(A), qui exige au moins trois administrateurs indépendants au sein du comité d’audit. Ce manquement a été provoqué par la démission du directeur Alan Edrick le 10 juin 2025, laissant seulement deux membres au comité d’audit. L’avis du Nasdaq a été reçu le 26 juin 2025.
HBIO indique qu’elle nommera un nouveau directeur entièrement indépendant « aussi rapidement que possible » et s’appuiera sur la période de correction prévue par la règle 5605(c)(4), accordant à la société jusqu’à la prochaine assemblée annuelle des actionnaires ou au 10 juin 2026, selon la première échéance, pour retrouver la conformité. Jusqu’à cette date, la société reste exposée à un éventuel retrait de cotation si elle ne nomme pas un directeur qualifié dans le délai imparti. Aucun état financier, indicateur de résultat ou détail transactionnel n’a été inclus dans ce dépôt.
Harvard Bioscience (HBIO) hat ein geändertes Formular 8-K eingereicht, um Punkt 3.01 zu berichtigen und zu bestätigen, dass die Nasdaq formell festgestellt hat, dass das Unternehmen gegen die Listing-Regel 5605(c)(2)(A) verstößt, die mindestens drei unabhängige Direktoren im Prüfungsausschuss vorschreibt. Der Mangel entstand durch den Rücktritt des Direktors Alan Edrick am 10. Juni 2025, wodurch nur noch zwei Mitglieder im Prüfungsausschuss verbleiben. Die Benachrichtigung von Nasdaq wurde am 26. Juni 2025 erhalten.
HBIO erklärt, dass es "so schnell wie möglich" einen neuen, vollständig unabhängigen Direktor ernennen wird und sich auf die Heilungsfrist in Regel 5605(c)(4) beruft, die dem Unternehmen bis zur nächsten jährlichen Hauptversammlung oder zum 10. Juni 2026, je nachdem, welches Datum früher eintritt, Zeit gibt, die Compliance wiederherzustellen. Bis dahin bleibt das Unternehmen potenziell von einem Delisting bedroht, falls kein qualifizierter Direktor innerhalb des erlaubten Zeitrahmens hinzugefügt wird. In dieser Einreichung sind keine Finanzberichte, Gewinnkennzahlen oder Transaktionsdetails enthalten.
UNITED STATES
SECURITIESAND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
(Amendment No. 1)
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities ExchangeAct of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
______________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of theAct:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the SecuritiesAct of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities ExchangeAct of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 3.01. | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On June 18, 2025, Harvard Bioscience, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the audit committee requirement set forth in Nasdaq Listing Rule 5605(c)(2)(A) (the “Audit Committee Composition Requirement”) due to the Company having only two members on the audit committee (the “Audit Committee”) of its Board of Directors (the “Board”). The Company’s current failure to comply with the Audit Committee Composition Requirement is due to a vacancy resulting from Alan Edrick’s resignation from the Board and the Audit Committee effective June 10, 2025.
On June 26, 2025, the Company received a letter from the staff at the Listing Qualifications Department of Nasdaq (the "Staff") notifying the Company that the Staff had determined that the Company no longer complies with the Audit Committee Composition Requirement.
The Company intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) by appointing a new Board member who meets the independence requirements under Nasdaq rules and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, as expeditiously as practicable. Until such appointment, the Company plans to rely on the cure period set forth in Nasdaq Listing Rule 5605(c)(4), which gives the Company until the earlier of (i) the Company’s next annual meeting of stockholders or (ii) one year from Mr. Edrick’s resignation, or June 10, 2026 to satisfy the Audit Committee Composition Requirement.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number | Description | |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities ExchangeAct of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HARVARD BIOSCIENCE, INC. | ||
| Date: June 27, 2025 | /s/ Mark Frost | |
| Mark Frost | ||
| Interim Chief Financial Officer and Treasurer | ||
FAQ
Why did Harvard Bioscience (HBIO) receive a Nasdaq deficiency notice?
What is the deadline for HBIO to regain compliance with Nasdaq's audit committee rule?
What action does HBIO plan to take to fix the audit committee shortfall?
Does the 8-K/A include any financial results or earnings information?
Could HBIO be delisted from Nasdaq?
